Total Payments
$9,775
2023 Payments
$9,661
Companies
6
Transactions
14
Medicare Patients
629
Medicare Billing
$78,848
Payment Breakdown by Category
Research$9,661 (98.8%)
Food & Beverage$114.71 (1.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9,661 | 7 | 98.8% |
| Food and Beverage | $114.71 | 7 | 1.2% |
Payments by Type
Research
$9,661
7 transactions
General
$114.71
7 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $9,661 | 7 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $40.81 | 3 | $0 (2017) |
| GlaxoSmithKline, LLC. | $24.81 | 1 | $0 (2017) |
| Grifols USA, LLC | $17.00 | 1 | $0 (2017) |
| Astellas Pharma US Inc | $16.52 | 1 | $0 (2017) |
| SANOFI-AVENTIS U.S. LLC | $15.57 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $9,661 | 7 | PFIZER INC. ($9,661) |
| 2017 | $114.71 | 7 | AstraZeneca Pharmaceuticals LP ($40.81) |
All Payment Transactions
14 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/26/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $4,012.00 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 09/26/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $2,006.00 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 05/25/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $174.28 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 05/25/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $100.00 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 05/11/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $1,413.60 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 05/04/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $1,905.70 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 05/04/2023 | PFIZER INC. | NURTEC ODT (Drug) | — | Cash or cash equivalent | $48.94 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE • Category: PAIN | ||||||
| 11/02/2017 | GlaxoSmithKline, LLC. | BEXSERO (Biological) | Food and Beverage | In-kind items and services | $24.81 | General |
| Category: VACCINES | ||||||
| 09/27/2017 | Grifols USA, LLC | Prolastin-C (Biological) | Food and Beverage | In-kind items and services | $17.00 | General |
| Category: Pulmonology | ||||||
| 07/24/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.64 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/11/2017 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $11.03 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/19/2017 | SANOFI-AVENTIS U.S. LLC | DIABETES - DISEASE (Drug) | Food and Beverage | In-kind items and services | $15.57 | General |
| 02/23/2017 | Astellas Pharma US Inc | Myrbetriq (Drug) | Food and Beverage | In-kind items and services | $16.52 | General |
| Category: Urology | ||||||
| 01/24/2017 | AstraZeneca Pharmaceuticals LP | SYMBICORT (Drug) | Food and Beverage | In-kind items and services | $11.14 | General |
| Category: Respiratory | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $9,661 | 7 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 218 | 784 | $112,205 | $34,555 |
| 2022 | 15 | 288 | 629 | $111,891 | $34,112 |
| 2021 | 7 | 123 | 389 | $29,376 | $10,181 |
Total Patients
629
Total Services
1,802
Medicare Billing
$78,848
Procedure Codes
35
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2023 | 18 | 263 | $19,725 | $8,059 | 40.9% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2023 | 18 | 149 | $18,625 | $5,269 | 28.3% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2023 | 17 | 152 | $22,800 | $5,242 | 23.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 26 | 53 | $10,600 | $4,637 | 43.7% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2023 | 12 | 12 | $5,400 | $2,292 | 42.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 26 | 43 | $7,525 | $2,208 | 29.3% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 13 | 13 | $2,665 | $1,657 | 62.2% |
| 93930 | Ultrasound of arm arteries or artery grafts | Office | 2023 | 12 | 12 | $5,400 | $1,491 | 27.6% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 12 | 12 | $7,200 | $1,452 | 20.2% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 12 | 12 | $5,400 | $1,267 | 23.5% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 12 | 12 | $5,400 | $564.85 | 10.5% |
| G0444 | Annual depression screening, 5 to 15 minutes | Office | 2023 | 19 | 19 | $665.00 | $346.75 | 52.1% |
| 81003 | Automated urinalysis test | Office | 2023 | 21 | 32 | $800.00 | $70.40 | 8.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 25 | 59 | $11,800 | $5,364 | 45.5% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 17 | 97 | $14,550 | $4,210 | 28.9% |
| 93925 | Ultrasound of leg arteries or artery grafts | Office | 2022 | 21 | 21 | $9,450 | $4,160 | 44.0% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 17 | 96 | $12,000 | $3,768 | 31.4% |
| 99458 | Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | Office | 2022 | 17 | 118 | $8,850 | $3,767 | 42.6% |
| 93930 | Ultrasound of arm arteries or artery grafts | Office | 2022 | 21 | 21 | $9,450 | $2,682 | 28.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 22 | 41 | $7,175 | $2,428 | 33.8% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2022 | 21 | 21 | $12,600 | $2,386 | 18.9% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2022 | 21 | 21 | $9,450 | $2,195 | 23.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 13 | 13 | $2,665 | $1,693 | 63.5% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2022 | 21 | 21 | $9,450 | $784.00 | 8.3% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 16 | 16 | $560.00 | $294.37 | 52.6% |
About Dr. Raymond Easley, D.O
Dr. Raymond Easley, D.O is a Family Medicine healthcare provider based in Cumming, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/22/2005. The National Provider Identifier (NPI) number assigned to this provider is 1255323655.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Raymond Easley, D.O has received a total of $9,775 in payments from pharmaceutical and medical device companies, with $9,661 received in 2023. These payments were reported across 14 transactions from 6 companies. The most common payment nature is "" ($9,661).
As a Medicare-enrolled provider, Easley has provided services to 629 Medicare beneficiaries, totaling 1,802 services with total Medicare billing of $78,848. Data is available for 3 years (2021–2023), covering 35 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Cumming, GA
- Active Since 08/22/2005
- Last Updated 02/08/2016
- Taxonomy Code 207Q00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1255323655
Products in Payments
- NURTEC ODT (Drug) $9,661
- FARXIGA (Drug) $29.67
- BEXSERO (Biological) $24.81
- Prolastin-C (Biological) $17.00
- Myrbetriq (Drug) $16.52
- DIABETES - DISEASE (Drug) $15.57
- SYMBICORT (Drug) $11.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Cumming
Charles Decook, Md, MD
Family Medicine — Payments: $27.1M
Family Medicine $27.1M
Dr. Nadine Halliburton-Foster, Md, MD
Family Medicine — Payments: $171,404
Family Medicine $171,404
Michelle Jenkins, M.d, M.D
Family Medicine — Payments: $16,081
Family Medicine $16,081
Jeevana Krishna, M.d, M.D
Family Medicine — Payments: $8,673
Family Medicine $8,673
Ryan Schott, Pa-C, PA-C
Family Medicine — Payments: $8,211
Family Medicine $8,211
Dr. Brent Carroll, D.o, D.O
Family Medicine — Payments: $5,693
Family Medicine $5,693